Skip to main content
BIIB logo

Biogen Inc. (BIIB) Stock: Price, Forecast & Analyst Target

Biogen Inc. (BIIB) — MoonshotScore 37/100 (Weak band), calculated Nov 18, 2026. Price $251.41 (+0.25%), as of the Nov 18, 2026 trading session; market cap $37.2B. Expected results Feb 5, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$251.41 +$0.62 (+0.25%) Market Cap $37.2B

Biogen Inc. · BIIB · NASDAQ · Healthcare · Drug Manufacturers - General

Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Biogen sells branded therapies for neurological and neurodegenerative diseases, led by its multiple sclerosis franchise and Spinraza for spinal muscular atrophy. It is less a broad drug manufacturer than a concentrated neuroscience business whose results depend on the durability of established products, partnered medicines and successful pipeline renewal. The defining question is whether diversification beyond mature multiple sclerosis therapies can strengthen earnings before pipeline spending and debt narrow the financial room for error.

Price as of Nov 18, 2026

Key Statistics

37 of 100

MoonshotScore v2 · Biogen (BIIB)

Weak
Business Quality Solid (77)
Financial Safety Strained (29)
Valuation Full (58)
Growth Durability Shrinking (15)
Momentum Surging (92)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a strained balance sheet and stalling growth — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.

  • EPS beat 7 of the last 8 reports
  • expected results Feb 5, 2027
  • Altman Z 3.15 · Piotroski F 4

Holding back: balance-sheet strain, soft growth

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BIIB (57 recorded, newest six shown)
RecordedScoreBand
41Weak
38Weak
38Weak
38Weak
37Weak
37Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$251.41
Change on the day+0.25%
52-week range$160.36–$261.00
Market capitalisation$37.2B—
Price / earnings (trailing)106.27
Shares traded on the day1.14M
Beta (volatility vs the S&P 500)0.17

Why Biogen scores 37

Dr. Mira Sol, the Stock Expert AI TV data character
Momentum carries the score; Growth Durability is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
37Weak
  • Business Quality77
  • Financial Safety29
  • Valuation58
  • Growth Durability15
  • Momentum92

Share price, last 12 months +53.8%

$164.73 $253.40

What the price assumes

5.9% a year of free-cash-flow growth for ten years is what a $37.46B market value ( snapshot) asks for.

  • Price implies, next ten years5.9%
  • Free cash flow, last 5 years-11.6%
  • Revenue, last 5 years-6.1%
  • Analysts' revenue path, 2026–20302.3%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $2.05B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 10 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 3.7% either way.

  1. -9.8%Feb ’24
  2. +4.8%Apr ’24
  3. -3.5%Aug ’24
  4. -5.2%Oct ’24
  5. -0.7%Feb ’25
  6. +2.0%May ’25
  7. +4.2%Jul ’25
  8. +4.3%Oct ’25
  9. +4.6%Feb ’26
  10. +3.2%Apr ’26
  11. +1.1%Jul ’26
  12. -1.2%Oct ’26
Next-session move EPS beat (10) EPS in line (1) EPS miss (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat-1.2%+0.7%
BeatBeat+1.1%+0.5%
BeatBeat+3.2%+4.0%
BeatBeat+4.6%+6.0%
BeatBeat+4.3%+6.0%
BeatBeat+4.2%+0.9%
BeatBeat+2.0%-2.2%
In lineBeat-0.7%-1.7%
BeatBeat-5.2%-4.9%
BeatMiss-3.5%-4.3%
BeatIn line+4.8%+11.9%
MissMiss-9.8%-9.7%

Beats have usually been rewarded — 7 of 10 drew a higher close the next session.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “high dose”, “appellis acquisition”, “spinraza high”, “another strong” — none of them came up in Q2 FY2026.
  • Getting louder: “core pharmaceutical” (2 → 4 mentions), “inventory dynamics” (1 → 4 mentions).
  • Gone quiet: “apellis transaction”, “biib dirinersen”, “btk inhibitor”, “early-stage pipeline” — regular themes last call, absent this time.
  • Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.1 to 0.8 per 1,000 words, and confident words such as “record” and “strong” fell from 4 to 3.1.

Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.

Our track record on this stock

Since the score went from 64 to 37 while the share price moved +15.3% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range
Band changes, newest first. “Right” means the price moved the way the change pointed over the next three months.
DateBand3 months6 monthsCall
Strong → Weak———
Fair → Strong———
Strong → Fair———
Fair → Strong———
Strong → Fair———
Fair → Strong———

None of the 10 band changes we have recorded has been graded yet; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 67% of 49 rate it a buy; the average target sits +4.1% from the price of $251.41.
  • Last 90 days: 2 upgrades and 0 downgrades among 23 rating actions.
  • Our signals: Weak band; strongest pillar Momentum (92), weakest Growth Durability (15).

The crowd is more enthusiastic than our signals. Our Growth Durability reading is the main reason.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $143, high $254, latest $251. $254 $143 high $254 Oct 17, 2025 Nov 18, 2026 · $251 $143Oct 17, 2025$154Oct 31, 2025$168Nov 14, 2025$182Nov 28, 2025$174Dec 12, 2025$177Dec 26, 2025$188Jan 9, 2026$172Jan 23, 2026$201Feb 6, 2026$192Feb 20, 2026$185Mar 6, 2026$181Mar 20, 2026$177Apr 2, 2026$177Apr 17, 2026$187May 1, 2026$193May 15, 2026$196May 29, 2026$200Jun 12, 2026$216Jun 26, 2026$199Jul 10, 2026$202Jul 24, 2026$208Aug 7, 2026$217Aug 21, 2026$221Sep 4, 2026$216Sep 18, 2026$220Oct 2, 2026$233Oct 16, 2026$254Oct 30, 2026$253Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Biogen (BIIB): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Neutral
Growth Durability Negative
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Overvalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Neutral
ROE Weak
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Biogen (BIIB), and what does it report?

Short answer · as of

Biogen discovers, develops and commercializes medicines, while also participating in biosimilars and collaboration arrangements.

Demand is measured through sales of named therapies rather than patient services or research contracts, so product use, competitive persistence and partner execution drive the commercial result.

The disclosed revenue mix remains centered on multiple sclerosis products. Tysabri, fumarates and interferons are separately visible within that franchise, while Spinraza contributes exposure to spinal muscular atrophy; this concentration is more informative than the broad drug-manufacturer classification.

2 · Latest results

What do the latest results show for Biogen (BIIB)?

The latest period brought a revenue rebound and another result above the prevailing revenue and earnings estimates. The accounting outcome was less impressive: gross profit declined, selling and administrative expense rose, and operating income, net income and reported earnings per share all weakened despite higher sales.

Management says its core operating expense outlook incorporates investment across early-stage and late-stage pipeline programs. That identifies the spending priority, but it does not explain the revenue rebound; the reported statements show that improved sales have not yet translated into consistent operating leverage.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$2.80B-$21M-$0.14 (diluted)
Jun 2026$2.74B$98M$0.66 (diluted)
Mar 2026$2.48B$320M$2.15 (diluted)
Dec 2025$2.28B-$49M-$0.33 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Biogen (BIIB)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow remained positive throughout the reported series, with capital expenditure modest relative to cash generated. That supports continued research investment from the business itself, although annual net income declined even as revenue edged higher, and trailing profitability and returns remain restrained.

Debt substantially exceeds cash and investments. Cash and short-term investments also fell sharply in the latest period after previously building, leaving the closing balance below the opening level of the reported window. Near-term asset coverage remains adequate, but the net debt position makes durable cash conversion more important than headline liquidity alone.

The quality and distress screens are mixed rather than emphatic. Combined with uneven operating profit and earnings across recent periods, they argue for watching financial direction instead of treating any isolated result as representative.

4 · What to check next?

What should you watch next at Biogen (BIIB)?

Short answer · as of

The next earnings report is expected on Feb 5, 2027. The number it tests is the $12.51 EPS analysts carry for it.

At the forthcoming earnings release, watch whether revenue holds near its recent rebound while gross profit and operating income recover. Biogen has repeatedly exceeded prevailing estimates, but the latest income statement shows that another revenue beat would not by itself establish better earnings quality.

Product disclosures should reveal whether Tysabri, fumarates and interferons still carry most of the mix, and whether Spinraza and the broader portfolio are reducing that dependence. Longer-range estimates assume gradual revenue and earnings expansion, so sustained diversification matters more than an isolated reporting surprise.

Cash flow, debt and the reduced cash balance deserve attention after recent acquisition activity and material agreements. Management has already incorporated pipeline investment into its expense outlook; the useful confirmation would be continued operating cash generation without further pressure on financial flexibility.

5 · Peer comparison

How does Biogen compare with its peers?

Short answer

Biogen's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Biogen differs from more diversified drugmakers because its reported commercial base revolves around neuroscience franchises, especially multiple sclerosis. Spinraza adds a distinct neuromuscular business, while biosimilars, immunology products and collaboration arrangements broaden the model without changing its underlying concentration.

That structure makes the persistence of Tysabri, fumarates and interferons unusually visible in the revenue mix. Comparable businesses with broader therapeutic portfolios may spread product pressure across more franchises; Biogen instead relies more directly on neuroscience portfolio renewal and execution with named partners.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Named competitor$82.52 Nov 18, 2026$30.8B93 5-pillar Nov 18, 2026
STERIS plc (STE) Named competitor$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Sanofi (SNY) Same industry, near in market value$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$59.56 Nov 18, 2026$122B85 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Same industry, near in market value$178.76 Nov 18, 2026$277B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Same industry, near in market value$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
Novartis AG (NVS) Same industry, near in market value$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
GSK plc (GSK) Same industry, near in market value$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Named competitor$259.52 Nov 18, 2026$28.6B74 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Same industry, near in market value$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Biogen (BIIB) — this page$251.41$37.2B37

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$175.00 – $325.00
Consensus target
$261.83
Median target
$257.00
Revenue estimate
$10.60B
EPS estimate
$12.51

Consensus record · Captured .

Measured against a quoted price of $251.41 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 30, 2026

Transactions
21
Identified insiders
12
Purchases
0
Sales
2
Other transactions
19

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BIIB in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BIIB in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Biogen (BIIB)?

Read these with our analysis →

BIIB Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

How dependent is Biogen on Tysabri and its multiple sclerosis portfolio?

Multiple sclerosis products remain the largest disclosed commercial grouping, with Tysabri, fumarates and interferons all contributing meaningful revenue. Their durability therefore has an outsized influence on whether growth elsewhere changes Biogen’s overall trajectory.

What role does Spinraza play in Biogen’s business mix?

Spinraza gives Biogen a substantial spinal muscular atrophy franchise outside its multiple sclerosis base. It diversifies the disease exposure, but the disclosed mix still leaves multiple sclerosis as the dominant grouping.

Why did Biogen’s latest revenue rebound not produce stronger profit?

The income statement shows lower gross profit, higher selling and administrative expense, and weaker operating and net income despite increased revenue. Research expense eased, so the broader cost and gross-profit pattern prevented the sales improvement from flowing through cleanly.

What should investors watch in Biogen’s pipeline spending plan?

Management says the operating expense outlook includes investment in early-stage and late-stage pipeline programs. The practical test is whether that spending remains compatible with positive operating cash flow while the cash balance is lower and debt remains substantial.

What is the BIIB stock price today?

The last price recorded for Biogen Inc. (BIIB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BIIB price target?

The analyst consensus price target for Biogen Inc. (BIIB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Cash, investments and debt
  • 1. What is Biogen (BIIB), and what does it report?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • 2. What do the latest results show for Biogen (BIIB)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Biogen (BIIB)?: Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Distress and quality screens; Quarterly income statement (USD thousands)
  • 4. What should you watch next at Biogen (BIIB)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Revenue by segment; Analyst revenue and earnings estimates (average); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Recent SEC filings; Management outlook — dated call excerpts
  • 5. How does Biogen compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment
  • FAQ: How dependent is Biogen on Tysabri and its multiple sclerosis portfolio?: Revenue by segment; Business description
  • FAQ: What role does Spinraza play in Biogen’s business mix?: Revenue by segment; Business description
  • FAQ: Why did Biogen’s latest revenue rebound not produce stronger profit?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • FAQ: What should investors watch in Biogen’s pipeline spending plan?: Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold BIIB

Funds in our ETF coverage that list BIIB among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Neuroscience and Healthcare ETF (IBRN)4.36%
The Free Markets ETF (FMKT)3.40%